Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

Impact · against what's priced in

Scancell (SCLP) remains in a precarious liquidity position where the stock's value depends entirely on the October 20 vote to merge and secure $75 million in funding. While the FDA/MHRA clearance for a Phase III melanoma trial is a positive milestone, it increases the capital urgency given the current £5.3 million cash balance against a £17.4 million annual loss.

EEE+0.40: No priced-in read yet

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

What matters in this story

Quantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

What matters in this story

Quantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company

How each ticker is affected

Connected tickers

Track these names every morning.

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Dun & Bradstreet Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DNB

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

ROSEN, A LEADING LAW FIRM, Encourages Dun & Bradstreet Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DNB

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

What matters in this story

Next reads from the same story arc

Quantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

What matters in this story

Next reads from the same story arc

Quantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company

How each ticker is affected

Connected tickers

Track these names every morning.

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Dun & Bradstreet Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DNB

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

ROSEN, A LEADING LAW FIRM, Encourages Dun & Bradstreet Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DNB